Skip to main content

Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.

Publication ,  Journal Article
Rose, JE; Behm, FM; Westman, EC
Published in: Exp Clin Psychopharmacol
August 1998

The nicotinic antagonist mecamylamine was evaluated in a randomized smoking cessation trial. Four groups of participants (n = 20 per group) received nicotine plus mecamylamine, nicotine alone, mecamylamine alone, or no drug for 4 weeks before cessation. After the quit-smoking date, all subjects received nicotine plus mecamylamine treatment for 6 weeks. Nicotine skin patches (21 mg/24 hr) and mecamylamine capsules (2.5-5.0 mg twice per day) were used. Precessation mecamylamine significantly prolonged the duration of continuous smoking abstinence; abstinence rates at the end of treatment were 47.5% with mecamylamine and 27.5% without mecamylamine. Nicotine + mecamylamine reduced ad lib smoking, smoking satisfaction, and craving more than either drug alone. Moreover, the orthostatic decrease in blood pressure caused by mecamylamine was offset by nicotine. Mecamylamine before smoking cessation may be an effective adjunct to nicotine patch therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Exp Clin Psychopharmacol

DOI

ISSN

1064-1297

Publication Date

August 1998

Volume

6

Issue

3

Start / End Page

331 / 343

Location

United States

Related Subject Headings

  • Tobacco Use Disorder
  • Time Factors
  • Substance Abuse
  • Smoking Cessation
  • North Carolina
  • Nicotinic Agonists
  • Nicotine
  • Mecamylamine
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rose, J. E., Behm, F. M., & Westman, E. C. (1998). Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol, 6(3), 331–343. https://doi.org/10.1037//1064-1297.6.3.331
Rose, J. E., F. M. Behm, and E. C. Westman. “Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.Exp Clin Psychopharmacol 6, no. 3 (August 1998): 331–43. https://doi.org/10.1037//1064-1297.6.3.331.
Rose JE, Behm FM, Westman EC. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol. 1998 Aug;6(3):331–43.
Rose, J. E., et al. “Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.Exp Clin Psychopharmacol, vol. 6, no. 3, Aug. 1998, pp. 331–43. Pubmed, doi:10.1037//1064-1297.6.3.331.
Rose JE, Behm FM, Westman EC. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol. 1998 Aug;6(3):331–343.

Published In

Exp Clin Psychopharmacol

DOI

ISSN

1064-1297

Publication Date

August 1998

Volume

6

Issue

3

Start / End Page

331 / 343

Location

United States

Related Subject Headings

  • Tobacco Use Disorder
  • Time Factors
  • Substance Abuse
  • Smoking Cessation
  • North Carolina
  • Nicotinic Agonists
  • Nicotine
  • Mecamylamine
  • Male
  • Humans